https://cerevel.com

Home Page - Cerevel TherapeuticsUnraveling the mysteries of the brain to treat neuroscience diseases Cerevel Therapeutics is working relentlessly to find paths through complexity in an effort to bring real progress and new treatment options to people living with some of the most devastating neuroscience diseases. Transforming what is possible in neuroscience We are a team of experts purpose-builtHome Page - Cerevel Therapeutics Skip to content Cerevel About CerevelAbout CerevelUnraveling the mysteries of the brainLeadership teamOur ProgramsOur ProgramsEmraclidineDarigabatTavapadonCVL-871Our ScienceOur ScienceOur scientific strategyOur pipelineHealthcare ProfessionalsHealthcare ProfessionalsPublicationsCongressesInvestors & MediaInvestors & MediaOverviewNews & EventsNews & EventsNews & AnnouncementsEventsPresentationsStockStockStock quote & chartHistoric price lookupInvestment calculatorAnalyst coverageFinancialsFinancialsSEC filingsAnnual reportsQuarterly resultsGovernanceGovernanceDocuments ChartersLeadership teamCommittee CompositionResourcesResourcesInvestor FAQsEmail alertsInvestor & Media ContactCareersCareersWorking at Cerevel TherapeuticsOpen PositionsFellowship ProgramsContact Us Unraveling the mysteries of the brain to treat neuroscience diseases Cerevel Therapeutics is working relentlessly to find paths through complexity in an effort to bring real progress and new treatment options to people living with some of the most devastating neuroscience diseases. Transforming what is possible in neuroscience We are a team of experts purpose-built to make intentional, rigorously evaluated decisions that are designed to deliver innovation in neuroscience. Learn more Unlocking new treatment opportunities by understanding how deficits in neurocircuitry drive the development of symptoms Devastating and life-threatening neuroscience diseases represent one of the greatest opportunities of our time to help the hundreds of millions of people affected worldwide. Addressing these underserved areas and communities is the focus of our research and development efforts. Learn more Our latest news AbbVie Completes Acquisition of Cerevel TherapeuticsAugust 1, 2024 Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseApril 18, 2024 AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience PipelineDecember 6, 2023 Read More Cerevel is now part of AbbVie Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders. Read the press release X Cerevel About CerevelAbout CerevelUnraveling the mysteries of the brainLeadership teamOur ProgramsOur ProgramsEmraclidineDarigabatTavapadonCVL-871Our ScienceOur ScienceOur scientific strategyOur pipelineHealthcare ProfessionalsHealthcare ProfessionalsInvestors & MediaInvestors & MediaOverviewNews & EventsNews & EventsPresentationsStockStockFinancialsFinancialsGovernanceGovernanceResourcesResourcesCareersCareersWorking at Cerevel TherapeuticsOpen PositionsFellowship ProgramsContact Us FacebookTwitterLinkedInYouTube Cerevel Terms of UsePrivacy PolicyFCOIEarly Access Program (EAP) Policy © 2024 Cerevel Therapeutics CEREVEL and the CEREVEL logo are trademarks of Cerevel Therapeutics. All Rights Reserved. You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites. Cancel OKenusen-US1729141347https://cerevel.com

Ahitsio ny tranokalanao?

Manao inona ianao?